Atlas of Oncology Genetics
This is a good resource for understanding the genetics of cancer cells etc.... link to site here
This is a good resource for understanding the genetics of cancer cells etc.... link to site here
You are here
Novartis Pregnancy Drug Exposure Registry for Female CML Patients
Novartis Oncology, the manufacturer of Gleevec® & Tasigna® has established this Pregnancy Drug Exposure Registry to learn about pregnancy outcomes and the health of women who have taken Gleevec® and/or Tasigna® within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy.
Novartis Oncology, the manufacturer of Gleevec® & Tasigna® has established this Pregnancy Drug Exposure Registry to learn about pregnancy outcomes and the health of women who have taken Gleevec® and/or Tasigna® within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy.
Patient's right to treatment - RCF's booklet
Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here
Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here
Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients
Capsule Summary CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients
Posting Date: December 12, 2008
Analysis[1] of pooled data from 2 phase II clinical trials: SRC-ABL Tyrosine Kinase Inhibition Activity Research Trial (START)–C and START-R
Summary of Key Conclusions
Cytogenetic responses rapidly attained with dasatinib 70 mg twice daily in imatinib-resistant/intolerant patients with chronic-phase chronic myeloid leukemia (CML)
89% of all complete cytogenetic responses achieved within first 12 months of treatment
47% of responses achieved within first 3 months of treatment
Cytogenetic responses highly durable with dasatinib therapy
91% of complete cytogenetic responses maintained during 24 months of follow-up
Achieving both major cytogenetic response and complete cytogenetic response at 12 months highly predictive for PFS
....read more
Capsule Summary CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients
Posting Date: December 12, 2008
Analysis[1] of pooled data from 2 phase II clinical trials: SRC-ABL Tyrosine Kinase Inhibition Activity Research Trial (START)–C and START-R
Summary of Key Conclusions
Cytogenetic responses rapidly attained with dasatinib 70 mg twice daily in imatinib-resistant/intolerant patients with chronic-phase chronic myeloid leukemia (CML)
89% of all complete cytogenetic responses achieved within first 12 months of treatment
47% of responses achieved within first 3 months of treatment
Cytogenetic responses highly durable with dasatinib therapy
91% of complete cytogenetic responses maintained during 24 months of follow-up
Achieving both major cytogenetic response and complete cytogenetic response at 12 months highly predictive for PFS
STIM Study Shows CML Complete Molecular Remission Possible to Maintain Following Imatinib Discontinuation
Summary Friday, December 19, 2008
Capsule SummaryCCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Summary Friday, December 19, 2008
Capsule SummaryCCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
SPIRIT: Higher MMR Rate With Imatinib/Peginterferon vs Imatinib Alone & Imatinib/Cytarabine in Patients with Newly Diagnosed CML
CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Template letters to PCT and MP's for those who cannot access dasatinib or nilotinib
These letters are templates which you can use when writing to your PCT and MP when challenging negative funding decisions for alternatives to imatinib. f You should change the wording to suit your individual details and situation.
These letters are templates which you can use when writing to your PCT and MP when challenging negative funding decisions for alternatives to imatinib. f You should change the wording to suit your individual details and situation.
Scientists have discovered how cancer spreads
Scientists may be able to stop cancer spreading round the body
Scientists have discovered how cancer spreads round the body raising the possibility it could be stopped.
Scientists may be able to stop cancer spreading round the body
Scientists have discovered how cancer spreads round the body raising the possibility it could be stopped.
New RCF report reveals striking postcode lottery
New RCF report reveals striking postcode lottery in the chances of having an exceptional request for cancer treatment approved
Monday, August 11, 2008
Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The audit found that:
New RCF report reveals striking postcode lottery in the chances of having an exceptional request for cancer treatment approved
Monday, August 11, 2008
Rarer Cancers Forum carried out an audit of the policies and processes used by PCTs to determine exceptional funding requests. The audit found that:
Patient's Right to Treatment: Applying for NHS Exceptional Funding for Treatment
YOUR PATIENT'S RIGHT TO TREATMENT,
written by Peter Telford
Your Patient's Right to Treatment: Applying for NHS Exceptional Funding for Treatment
This 32-page booklet was written by a barrister, Peter Telford. It was launched at
YOUR PATIENT'S RIGHT TO TREATMENT,
written by Peter Telford
Your Patient's Right to Treatment: Applying for NHS Exceptional Funding for Treatment
This 32-page booklet was written by a barrister, Peter Telford. It was launched at